RNA干扰疗法：靶向不可成药靶点的药物研发
RNAi therapies: drugging the undruggable.
作者信息
Wu Sherry Y, Lopez-Berestein Gabriel, Calin George A, Sood Anil K
机构信息
Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.
Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA. Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA.
出版信息
Sci Transl Med. 2014 Jun 11;6(240):240ps7. doi: 10.1126/scitranslmed.3008362.
Abstract
RNA interference (RNAi) therapy is a rapidly emerging platform for personalized cancer treatment. Recent advances in small interfering RNA delivery and target selection provide unprecedented opportunities for clinical translation. Here, we discuss these advances and present strategies for making RNAi-based therapy a viable part of cancer management.
摘要
RNA干扰（RNAi）疗法是一种迅速兴起的个性化癌症治疗平台。小干扰RNA递送和靶点选择方面的最新进展为临床转化提供了前所未有的机会。在此，我们讨论这些进展，并提出使基于RNAi的疗法成为癌症治疗可行部分的策略。
相似文献
1
RNAi therapies: drugging the undruggable.RNA干扰疗法：靶向不可成药靶点的药物研发
Sci Transl Med. 2014 Jun 11;6(240):240ps7. doi: 10.1126/scitranslmed.3008362.
2
An update on RNA interference-mediated gene silencing in cancer therapy.RNA干扰介导的基因沉默在癌症治疗中的最新进展。
Expert Opin Biol Ther. 2014 Nov;14(11):1581-92. doi: 10.1517/14712598.2014.935334. Epub 2014 Jul 10.
3
Delivery of RNA interference.RNA干扰的传递
Cell Cycle. 2006 Sep;5(18):2103-9. doi: 10.4161/cc.5.18.3192. Epub 2006 Sep 15.
4
RNA interference: gene silencing in the fast lane.RNA干扰：快速通道中的基因沉默
Semin Cancer Biol. 2003 Aug;13(4):259-65. doi: 10.1016/s1044-579x(03)00039-7.
5
Strategies for silencing human disease using RNA interference.利用RNA干扰沉默人类疾病的策略。
Nat Rev Genet. 2007 Mar;8(3):173-84. doi: 10.1038/nrg2006.
6
[Combinatorial RNAi and its application in cancer gene therapy].[组合RNA干扰及其在癌症基因治疗中的应用]
Yao Xue Xue Bao. 2012 May;47(5):573-9.
7
Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies.RNA 干扰介导的基因沉默的治疗潜力：原理、挑战与新策略。
Gene. 2014 Apr 1;538(2):217-27. doi: 10.1016/j.gene.2013.12.019. Epub 2014 Jan 7.
8
The dicey role of Dicer: implications for RNAi therapy.Dicer 的棘手角色：对 RNAi 治疗的影响。
Cancer Res. 2010 Apr 1;70(7):2571-4. doi: 10.1158/0008-5472.CAN-09-2536. Epub 2010 Feb 23.
9
Gene silencing of HIV-1 by RNA interference.通过RNA干扰实现HIV-1基因沉默。
Antivir Chem Chemother. 2004 Mar;15(2):57-65. doi: 10.1177/095632020401500201.
10
RNA interference and cancer therapy.RNA 干扰与癌症治疗。
Pharm Res. 2011 Dec;28(12):2983-95. doi: 10.1007/s11095-011-0604-5. Epub 2011 Oct 19.
引用本文的文献
1
siRNAs, tRNAs, and rRNAs in Osteoarthritis: Biological Functions and Therapeutic Opportunities.骨关节炎中的小干扰RNA、转运RNA和核糖体RNA：生物学功能与治疗前景
Biologics. 2025 Sep 3;19:539-560. doi: 10.2147/BTT.S521180. eCollection 2025.
2
Improving the Cellular Accumulation of Folate-Conjugated Fully Chemically Modified siRNAs via 3' Terminal Conjugation.通过3'末端共轭提高叶酸共轭的完全化学修饰小干扰RNA的细胞积累
ACS Omega. 2025 Jul 25;10(30):32744-32753. doi: 10.1021/acsomega.4c11519. eCollection 2025 Aug 5.
3
Trends and Commonalities of Approved and Late Clinical-Phase RNA Therapeutics.获批及临床后期RNA疗法的趋势与共性
Pharmaceutics. 2025 Jul 12;17(7):903. doi: 10.3390/pharmaceutics17070903.
4
Epigenetic Dysregulation in Cancer: Implications for Gene Expression and DNA Repair-Associated Pathways.癌症中的表观遗传失调：对基因表达和DNA修复相关通路的影响。
Int J Mol Sci. 2025 Jul 7;26(13):6531. doi: 10.3390/ijms26136531.
5
Inhibition of Factor XI Using RBD4059: A Novel GalNAc-siRNA With Potent and Durable Antithrombotic Effects.使用RBD4059抑制凝血因子XI：一种具有强效和持久抗血栓作用的新型GalNAc-siRNA
JACC Basic Transl Sci. 2025 Jun;10(6):786-797. doi: 10.1016/j.jacbts.2024.12.005. Epub 2025 Feb 19.
6
EphA2 blockage ALW-II-41-27 alleviates atherosclerosis by remodeling gut microbiota to regulate bile acid metabolism.EphA2 阻断剂 ALW-II-41-27 通过重塑肠道微生物群来调节胆汁酸代谢，从而缓解动脉粥样硬化。
NPJ Biofilms Microbiomes. 2024 Oct 19;10(1):108. doi: 10.1038/s41522-024-00585-7.
7
Potential therapies for non-coding RNAs in breast cancer.乳腺癌中非编码RNA的潜在治疗方法。
Front Oncol. 2024 Sep 20;14:1452666. doi: 10.3389/fonc.2024.1452666. eCollection 2024.
8
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.外泌体介导的siRNA分子在癌症治疗中的应用：成就与挑战
Front Mol Biosci. 2024 Sep 17;11:1447953. doi: 10.3389/fmolb.2024.1447953. eCollection 2024.
9
Delivery of nucleic acids using nanomaterials.使用纳米材料递送核酸。
Mol Biomed. 2023 Dec 14;4(1):48. doi: 10.1186/s43556-023-00160-0.
10
In vivo self-assembly and delivery of VEGFR2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.体内自组装和递送 VEGFR2siRNA 包裹的小细胞外囊泡用于治疗肺转移骨肉瘤。
Cell Death Dis. 2023 Sep 22;14(9):626. doi: 10.1038/s41419-023-06159-3.
本文引用的文献
1
2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.2'-O-甲基-磷酰二硫代酸修饰的小干扰RNA显示出进入RNA诱导沉默复合体的装载增加以及抗肿瘤活性增强。
Nat Commun. 2014 Mar 12;5:3459. doi: 10.1038/ncomms4459.
2
Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.纳米颗粒介导的CDK4小干扰RNA递送用于KRAS突变型非小细胞肺癌的合成致死疗法
Mol Ther. 2014 May;22(5):964-73. doi: 10.1038/mt.2014.18. Epub 2014 Feb 5.
3
Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas.直接体内 RNAi 筛选揭示肌球蛋白 IIa 是鳞状细胞癌的肿瘤抑制因子。
Science. 2014 Jan 17;343(6168):309-13. doi: 10.1126/science.1248627.
4
Synthetic lethality between CCNE1 amplification and loss of BRCA1.CCNE1 扩增与 BRCA1 缺失之间的合成致死性。
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94. doi: 10.1073/pnas.1314302110. Epub 2013 Nov 11.
5
Exploiting endocytosis for nanomedicines.利用内吞作用研发纳米药物。
Cold Spring Harb Perspect Biol. 2013 Nov 1;5(11):a016980. doi: 10.1101/cshperspect.a016980.
6
Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.miRNA 和 siRNA 在卵巢癌治疗中的治疗协同作用。
Cancer Discov. 2013 Nov;3(11):1302-15. doi: 10.1158/2159-8290.CD-13-0159. Epub 2013 Sep 3.
7
Safety and efficacy of RNAi therapy for transthyretin amyloidosis.RNAi 疗法治疗转甲状腺素淀粉样变性的安全性和有效性。
N Engl J Med. 2013 Aug 29;369(9):819-29. doi: 10.1056/NEJMoa1208760.
8
Signatures of mutational processes in human cancer.人类癌症中的突变过程特征。
Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14.
9
RNAi screens in mice identify physiological regulators of oncogenic growth.RNAi 筛选在小鼠中鉴定出致癌生长的生理调节剂。
Nature. 2013 Sep 12;501(7466):185-90. doi: 10.1038/nature12464. Epub 2013 Aug 14.
10
Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.可生物降解脂质使 RNAi 治疗药物的全身递送系统能够快速消除脂质纳米颗粒。
Mol Ther. 2013 Aug;21(8):1570-8. doi: 10.1038/mt.2013.124. Epub 2013 Jun 25.
Zotero 插件